Open Access. Powered by Scholars. Published by Universities.®
Pharmacy Administration, Policy and Regulation Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Health Law and Policy (3)
- Law (3)
- Pharmacoeconomics and Pharmaceutical Economics (3)
- Administrative Law (1)
- Chemicals and Drugs (1)
-
- Commercial Law (1)
- Education (1)
- Food and Drug Law (1)
- Intellectual Property Law (1)
- Mathematics (1)
- Nursing (1)
- Other Pharmacy and Pharmaceutical Sciences (1)
- Pharmaceutical Preparations (1)
- Physical Sciences and Mathematics (1)
- Social Work (1)
- Social and Behavioral Sciences (1)
- Vocational Education (1)
- Institution
- Publication
- Publication Type
Articles 1 - 7 of 7
Full-Text Articles in Pharmacy Administration, Policy and Regulation
Will Reducing Drug Prices Slow Innovation?, Gregory Vaughan, Fred Ledley
Will Reducing Drug Prices Slow Innovation?, Gregory Vaughan, Fred Ledley
Mathematical Sciences Faculty Publications
The pharmaceutical industry has long argued that high drug prices reflect the high cost of innovation and that reducing drug prices would necessarily slow the pipeline of new drugs. These arguments have been bolstered by studies of large pharmaceutical companies showing statistical associations between the projected market size or revenue for pharmaceutical products and research & development (R&D) activity. Our analysis recognizes the increasingly important role of small biopharmaceuticals in drug development , companies that typically have little revenue and negative earnings, but are now responsible for more than 40% of new drug approvals. We examine the relationship between changes …
Will Reducing Drug Prices Slow Innovation?, Gregory Vaughan, Fred Ledley
Will Reducing Drug Prices Slow Innovation?, Gregory Vaughan, Fred Ledley
Natural & Applied Sciences Faculty Publications
The pharmaceutical industry has long argued that high drug prices reflect the high cost of innovation and that reducing drug prices would necessarily slow the pipeline of new drugs. These arguments have been bolstered by studies of large pharmaceutical companies showing statistical associations between the projected market size or revenue for pharmaceutical products and research & development (R&D) activity. Our analysis recognizes the increasingly important role of small biopharmaceuticals in drug development , companies that typically have little revenue and negative earnings, but are now responsible for more than 40% of new drug approvals. We examine the relationship between changes …
Guidelines On Prescriptive Authority For Nurses 2021, David Stewart, Madrean Schober, Lisa Nissen, Elissa Ladd, Kimberley Lamarche, Marie-Lyne Bournival, Deborah Gray, Sonia Sevilla, Marieke Kroezen, Frances Wong
Guidelines On Prescriptive Authority For Nurses 2021, David Stewart, Madrean Schober, Lisa Nissen, Elissa Ladd, Kimberley Lamarche, Marie-Lyne Bournival, Deborah Gray, Sonia Sevilla, Marieke Kroezen, Frances Wong
Ellmer School of Nursing Faculty Publications
[First paragraph] Nurse prescribing has existed for over 50 years in some regions of the world. The diverse global nurse prescriptive authority landscape will be highlighted in this important publication. A framework embedding core components for safe and competent prescribers necessitates appropriate education, aligned regulatory authority and continuing professional development to uphold competencies. Evidence-informed models of nurse prescribing will weave in organisational and team support considerations required.
Harmful Or Helpful? Direct To Consumer Advertising, Sally A. Kiss
Harmful Or Helpful? Direct To Consumer Advertising, Sally A. Kiss
The Graduate Review
Policy change in 1997 by the Food and Drug Administration made the United States only one of two countries to allow direct-to-consumer advertising (DTCA). DTCA refers to the promotion of prescription medications through media directly to consumers as opposed to distribution of information only medical professionals. Supporters argue that DTCA educates consumers and helps them to make more informed decisions about their health care. On the other side, opponents argue that it leads to otherwise healthy people believing they are sick, thereby increasing profits for pharmaceutical companies. After reviewing the history of DTCA and literature demonstrating the pros and cons …
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, W. Nicholson Price Ii
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, W. Nicholson Price Ii
Law Faculty Scholarship
Despite increasing recalls, contamination events, and shortages, drug companies continue to rely on outdated manufacturing plants and processes. Drug manufacturing’s inefficiency and lack of innovation stand in stark contrast to drug discovery, which is the focus of a calibrated innovation policy that combines patents and FDA regulation. Pharmaceutical manufacturing lags far behind the innovative techniques found in other industries due to high regulatory barriers and ineffective intellectual property incentives. Among other challenges, although manufacturers tend to rely on trade secrecy because of the difficulty in enforcing patents on manufacturing processes, trade secrecy provides limited incentives for innovation. To increase those …
Shrinking Drug Costs Without Silencing Pharmaceutical Detailers: Maryland's Options After Sorrell V. Ims Health, Kristina L. Miller
Shrinking Drug Costs Without Silencing Pharmaceutical Detailers: Maryland's Options After Sorrell V. Ims Health, Kristina L. Miller
Journal of Health Care Law and Policy
No abstract provided.
Patient Perceptions Of Drug Risks And Benefits, Michael S. Brown, Linda J. Wastila, Carol I. Baras, Louis Lasagna
Patient Perceptions Of Drug Risks And Benefits, Michael S. Brown, Linda J. Wastila, Carol I. Baras, Louis Lasagna
RISK: Health, Safety & Environment (1990-2002)
This is a report of a pilot study conducted to examine patients' perceptions of drug Risks and benefits. While all of the factors influencing such perceptions are important, the findings about the extent to which views are affected by patient understanding of and confidence in regulatory oversight should be of professional interest to an especially broad audience.